Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080798 | 1.00 | HTT (0.55) | HTTEP300KAT2BCA12CA1 | |
| Hydrochloric Acid SCHEMBL30385194 | 0.98 | HTT (0.53) | HTTEP300KAT2BCA12CA1 | |
| SCHEMBL31063913 | 0.83 | CA12 (0.41) | HTTEP300KAT2BCA12CA1 | |
| SCHEMBL31134347 | 0.83 | CYP2A6 (0.50) | HTTEP300KAT2BCA12CA1 | |
| SCHEMBL31134309 | 0.83 | CA12 (0.41) | HTTEP300KAT2BCA12CA1 | |
| SCHEMBL3561936 | 0.79 | CA12 (0.50) | EP300KAT2BCA12CA1CA2 | |
| SCHEMBL143175 | 0.78 | ALDH1A1 (0.54) | EP300KAT2BF10GAAMAPT | |
| SCHEMBL1044182 | 0.76 | ELANE (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL31310093 | 0.76 | CYP2A6 (0.46) | HTTEP300KAT2BCYP2A6CYP3A4 | |
| SCHEMBL27990226 | 0.76 | CA12 (0.48) | EP300KAT2BCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768671-B1 | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2024-05-22 | — | — | EP | claimed |
| US-11542275-B2 | Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-03 | — | — | US | claimed |
| EP-0127756-A1 | Process for the preparation of 5-pyridyl-pyridine-2(1H)-ones | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1984-12-12 | — | — | EP | claimed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-120476110-B | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4590396-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| WO-2014074660-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2648516-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Confluence Life Sciences, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| EP-0127756-B1 | PROCESS FOR THE PREPARATION OF 5-PYRIDYL-PYRIDINE-2(1H)-ONES | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1988-10-26 | — | — | EP | disclosed |
| US-4563528-A | Process for preparing 5 pyridyl pyridine-2 (1H)-ones | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1986-01-07 | — | — | US | disclosed |
| EP-0127756-A1 | Process for the preparation of 5-pyridyl-pyridine-2(1H)-ones | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1984-12-12 | — | — | EP | disclosed |
| EP-0127756-A1 | Process for the preparation of 5-pyridyl-pyridine-2(1H)-ones | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1984-12-12 | — | — | EP | disclosed |
| EP-0127756-A1 | Process for the preparation of 5-pyridyl-pyridine-2(1H)-ones | FABRICA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS ABELLO, S.A. (ES) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542275-B2 | Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors | PRMT5, PRMT1, PRMT8 | HTT 3608/4885EP300 868/4885KAT2B 1378/4885 |
| US-20120142709-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K6 | HTT 4247/4885EP300 1152/4885KAT2B 2688/4885 |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | HTT 1422/4885EP300 2725/4885KAT2B 1466/4885 |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | WEE1, WEE2, NOS1 | HTT 1356/4885EP300 3523/4885KAT2B 3687/4885 |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, NOS1 | HTT 1356/4885EP300 3523/4885KAT2B 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.